Zika Virus Infection

Debbie-Ann T Shirley; James P Nataro

doi:10.1016/j.pcl.2017.03.012

Zika Virus Infection

Pediatr Clin North Am. 2017 Aug;64(4):937-951. doi: 10.1016/j.pcl.2017.03.012.

Authors

Debbie-Ann T Shirley¹, James P Nataro²

Affiliations

¹ Department of Pediatrics, University of Virginia School of Medicine, Box 800386, Charlottesville, VA 22908-0386, USA. Electronic address: ds3ru@virginia.edu.
² Department of Pediatrics, University of Virginia School of Medicine, Box 800386, Charlottesville, VA 22908-0386, USA.

PMID: 28734519
DOI: 10.1016/j.pcl.2017.03.012

Abstract

In less than 2 years since entry into the Americas, we have witnessed the emergent spread of Zika virus into large subsets of immunologically naïve human populations and then encountered the devastating effects of microcephaly and brain anomalies that can arise from in utero infection with the virus. Diagnostic evaluation and management of affected infants continues to evolve as our understanding of Zika virus rapidly advances. The development of a safe and effective vaccine holds the potential to attenuate the spread of infection and limit the impact of congenital infection.

Keywords: Congenital; Microcephaly; Mosquito; Sexual transmission; Travel; Zika.

Publication types

Review

MeSH terms

Antiviral Agents / therapeutic use*
Female
Humans
Infant
Microcephaly / virology
Pregnancy
Pregnancy Complications, Infectious / diagnosis*
Pregnancy Complications, Infectious / prevention & control
Vaccines, Inactivated / administration & dosage
Zika Virus Infection / diagnosis*
Zika Virus Infection / prevention & control
Zika Virus*

Substances

Antiviral Agents
Vaccines, Inactivated